Garland Jonathan Todd 4
4 · Cytek Biosciences, Inc. · Filed May 19, 2023
Insider Transaction Report
Form 4
Garland Jonathan Todd
Chief Commercial Officer
Transactions
- Exercise/Conversion
Common Stock
2023-05-18+7,804→ 7,804 total - Tax Payment
Common Stock
2023-05-18$6.69/sh−717$4,797→ 5,887 total - Tax Payment
Common Stock
2023-05-18$6.69/sh−3,040$20,338→ 4,764 total - Exercise/Conversion
Common Stock
2023-05-18+1,840→ 6,604 total - Exercise/Conversion
Restricted Stock Units
2023-05-18−7,804→ 23,413 total→ Common Stock (7,804 underlying) - Exercise/Conversion
Restricted Stock Units
2023-05-18−1,840→ 42,340 total→ Common Stock (1,840 underlying)
Footnotes (4)
- [F1]Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.
- [F2]Represents the number of shares withheld by and surrendered to the Issuer on May 18, 2023, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award.
- [F3]The shares subject to the RSU Award shall vest quarterly over four years, with 12/48th of the total shares underlying the RSU Award vesting on May 18, 2023 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18.
- [F4]The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2024 and each March 10 thereafter, until fully vested.